Breaking News Instant updates and real-time market news.

AXON

Axovant Sciences

$13.45

-0.03 (-0.22%)

, LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

07:20
11/23/16
11/23
07:20
11/23/16
07:20

Axovant Sciences drops 18% after Lilly Alzheimer's study failure

Axovant (AXON) is developing its own drug for the treatment of patients with Alzheimer's disease. As previously reported, Eli Lilly (LLY) announced earlier that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease.

AXON

Axovant Sciences

$13.45

-0.03 (-0.22%)

LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

  • 29

    Nov

  • 04

    Dec

AXON Axovant Sciences
$13.45

-0.03 (-0.22%)

09/22/16
JMPS
09/22/16
NO CHANGE
JMPS
Axovant Sciences weakness an opportunity, says JMP Securities
09/22/16
CHDN
09/22/16
NO CHANGE
Target $8
CHDN
Sell
Recent failures of 5-HT6 competitors reinforce Axovant risks, says Chardan
After Lundbeck reported that its 5-HT6 antagonist, idalopirdine, did not meet the primary endpoint in the first of three phase III studies in mild-to-moderate Alzheimer's disease patients, Chardan analyst Gbola Amusa noted that this is the second recent failure of a mid-to-late-stage 5-HT6 antagonist coming on the heels of Pfizer's (PFE) prior miss. Amusa anticipates that some in the market will see limited read-across from Lundbeck to Axovant (AXON), but he thinks Pfizer's and Lundbeck's setbacks reinforce the risks for the 5-HT6 antagonist class in Alzheimer's. The analyst reiterates his Sell rating and $8 price target on Axovant shares.
09/22/16
HCWC
09/22/16
NO CHANGE
Target $35
HCWC
Buy
No read-through from idalopirdine to Axovant RVT-101, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein notes that Lundbeck announced that its idalopirdine missed its primary and secondary endpoints in the STARSHINE Phase 3 study in mild/moderate Alzheimer's disease. However, Fein says that idalopirdine miss does not shake his confidence in Axovant's RVT-101 as he believes Lundbeck may have simply not been able to dose idalopirdine high enough in the Phase 3 program, which minimizes read-through to Axovant's MINDSET Phase 3 study. He continues to believe that Axovant's own experimental Alzheimer's therapy is well positioned for a win. Fein reiterates a Buy rating and $35 price target on Axovant's shares. In afternoon trading, Axovant's stock has dropped almost 12% to $15.31 per share.
09/23/16
PIPR
09/23/16
NO CHANGE
Target $32
PIPR
Overweight
Axovant Sciences selloff provides entry point, says Piper Jaffray
Piper Jaffray analyst Charles Duncan believes yesterday's selloff in shares of Axovant Sciences provides an entry point into the name. Lundbeck's announcement that its first Phase III data with idalopirdine in Alzheimer's missed the primary endpoint does not have predictive value for the Axovant's ongoing RVT-101 Phase III study, Duncan tells investors in a research note. The analyst sees "several key differences" between the two candidates and Phase III programs. He believes RVT-101 is the best-in-class 5-HT6 candidate and thinks its MINDSET trial is well designed to show clinical benefit. Duncan reiterates an Overweight rating on Axovant with a $32 price target.
LLY Eli Lilly
$75.99

-0.65 (-0.85%)

11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/11/16
JEFF
11/11/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies bullish on Lilly regardless of Alzheimer's data
Jefferies analyst Jeffrey Holford believes shares of Eli Lilly "can work over time" regardless of Alzheimer's disease drug solanezumab's Phase III study outcome. The analyst, however, says he has enough confidence to recommend Lilly shares ahead of the EXPEDITION3 data readout. Holford increased his base case solanezumab peak sales to $5B. He says Lilly remains one of his top picks with a Buy rating and $100 price target.
11/15/16
JPMS
11/15/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees favorable risk/reward for Lilly into Alzheimer's data
JPMorgan analyst Chris Schott sees a favorable risk/reward profile for shares of Eli Lilly into the solanezumab data for Alzheimer's, which is expected by year-end. Favorable data from the EXPEDITION-3 trial would represent a catalyst not just for Lilly and other Alzheimer's associated names but for the biopharma space as a whole, Schott tells investors in a research note. The analyst expects 20%-plus share upside in the event the trial is successful on both primary and secondary endpoints. He assigns a 10%-20% probability to this outcome. Schott sees 10%-20% share upside for Lilly should the study hit on its primary but only shows a trend on secondary endpoints. He assigns a 50%-60% probability for this outcome. The analyst also sees a 10% move to the downside if the study fails both endpoints, an outcome he assigns a 20% probability. Schott reiterates an Overweight rating on Lilly with a $95 price target. He believes Lilly's "diverse range of pipeline opportunities" largely supports the valuation at current levels.
11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Neutral
Citi pegs potential Biogen downside to $287 on Lilly failure
In a research note dated yesterday, Citi analyst Robyn Karnauskas said shares of Biogen (BIIB) could fall to $286 should Eli Lilly's (LLY) Alzheimer's drug solanezumab fail in its Phase 3 study. After Lilly reported this morning that the trial failed, shares of Biogen are down 6%, or $18.60, to $299.51 in pre-market trading. Shares of Lilly are down 14%, or $10.77, to $65.22. Karnauskas estimated the downside range of Biogen on a failed solanezumab study at $287-$306. The analyst has a Neutral rating on Biogen.

TODAY'S FREE FLY STORIES

CELG

Celgene

$117.39

0.83 (0.71%)

07:35
12/07/16
12/07
07:35
12/07/16
07:35
Hot Stocks
Celgene announces tnAcity trial data of ABRAXANE to be presented at SABCS »

Celgene announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$67.79

0.09 (0.13%)

07:35
12/07/16
12/07
07:35
12/07/16
07:35
Hot Stocks
Harvest Hill to acquire Nutrament business from Nestle »

Brynwood Partners VII…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$9.45

0.77 (8.87%)

, SBUX

Starbucks

$57.44

-0.06 (-0.10%)

07:35
12/07/16
12/07
07:35
12/07/16
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

AMD

AMD

$9.45

0.77 (8.87%)

SBUX

Starbucks

$57.44

-0.06 (-0.10%)

ETE

Energy Transfer Equity

$16.56

0.49 (3.05%)

HPE

HP Enterprise

$23.96

-0.25 (-1.03%)

JBLU

JetBlue

$21.19

0.29 (1.39%)

SWKS

Skyworks

$76.17

1.35 (1.80%)

STLD

Steel Dynamics

$38.86

0.73 (1.91%)

Z

Zillow

$37.40

2.63 (7.56%)

TEX

Terex

$31.09

1.25 (4.19%)

DRI

Darden

$77.25

0.54 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

  • 14

    Dec

  • 20

    Dec

NUS

Nu Skin

$51.56

0.05 (0.10%)

07:34
12/07/16
12/07
07:34
12/07/16
07:34
Earnings
Nu Skin sees FY17 EPS $3.10-$3.25, consensus $3.31 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

SNCR

Synchronoss

$42.59

-6.41 (-13.08%)

, IL

Intralinks

$13.12

1.85 (16.42%)

07:34
12/07/16
12/07
07:34
12/07/16
07:34
Recommendations
Synchronoss, Intralinks analyst commentary  »

Synchronoss deal has…

SNCR

Synchronoss

$42.59

-6.41 (-13.08%)

IL

Intralinks

$13.12

1.85 (16.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

NVTA

Invitae

$6.98

-0.07 (-0.99%)

07:34
12/07/16
12/07
07:34
12/07/16
07:34
Hot Stocks
Invitae announces expansion of its breast cancer STAT panel »

Invitae announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$53.72

0.16 (0.30%)

07:33
12/07/16
12/07
07:33
12/07/16
07:33
Hot Stocks
Mallinckrodt reports results from IV acetaminophen health economic analysis »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

CTIX

Cellceutix

$1.14

-0.045 (-3.80%)

07:33
12/07/16
12/07
07:33
12/07/16
07:33
Hot Stocks
Cellceutix Phase 2 trial dose escalates in second cohort for Brilacidin »

Cellceutix announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$55.99

0.97 (1.76%)

, SFTBF

SoftBank

$62.00

1.93 (3.21%)

07:33
12/07/16
12/07
07:33
12/07/16
07:33
Recommendations
T-Mobile, SoftBank, Sprint, DISH, AT&T, Verizon analyst commentary  »

T-Mobile price target…

TMUS

T-Mobile

$55.99

0.97 (1.76%)

SFTBF

SoftBank

$62.00

1.93 (3.21%)

S

Sprint

$8.17

0.12 (1.49%)

DISH

DISH

$58.51

1.85 (3.27%)

T

AT&T

$39.35

0.72 (1.86%)

VZ

Verizon

$50.36

0.61 (1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 13

    Dec

  • 04

    Jan

  • 24

    Jan

NUS

Nu Skin

$51.56

0.05 (0.10%)

07:32
12/07/16
12/07
07:32
12/07/16
07:32
Hot Stocks
Nu Skin announces CEO transition plan »

Nu Skin Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

CAL

Caleres

$33.80

0.28 (0.84%)

07:31
12/07/16
12/07
07:31
12/07/16
07:31
Upgrade
Caleres rating change  »

Caleres upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPGI

S&P Global

$113.57

-0.71 (-0.62%)

, CMCSA

Comcast

$68.70

0.02 (0.03%)

07:31
12/07/16
12/07
07:31
12/07/16
07:31
Conference/Events
UBS to hold a conference »

44th Annual Global Media…

SPGI

S&P Global

$113.57

-0.71 (-0.62%)

CMCSA

Comcast

$68.70

0.02 (0.03%)

AMT

American Tower

$100.85

-1.19 (-1.17%)

HSNI

HSN, Inc.

$35.90

-0.2 (-0.55%)

TGNA

TEGNA

$22.63

0.35 (1.57%)

CNSL

Consolidated Communications

LBTYA

Liberty Global

$29.91

0.36 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 14

    Dec

TEVA

Teva

$35.03

-2.01 (-5.43%)

, COG

Cabot Oil & Gas

$23.57

-0.06 (-0.25%)

07:30
12/07/16
12/07
07:30
12/07/16
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

TEVA

Teva

$35.03

-2.01 (-5.43%)

COG

Cabot Oil & Gas

$23.57

-0.06 (-0.25%)

FTK

Flotek

$13.11

-0.47 (-3.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 03

    Apr

07:30
12/07/16
12/07
07:30
12/07/16
07:30
General news
Treasury Market Outlook: bond yields are several ticks lower globally »

Treasury Market Outlook:…

CBS

CBS

$60.97

0.16 (0.26%)

07:29
12/07/16
12/07
07:29
12/07/16
07:29
Recommendations
CBS analyst commentary  »

CBS remains a top pick at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

P

Pandora

$13.78

0.41 (3.07%)

07:29
12/07/16
12/07
07:29
12/07/16
07:29
Recommendations
Pandora analyst commentary  »

Pandora Premium will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNCE

Snyder's-Lance

$36.81

0.23 (0.63%)

, LVS

Las Vegas Sands

$62.47

1.35 (2.21%)

07:29
12/07/16
12/07
07:29
12/07/16
07:29
Conference/Events
Bernstein to hold a summit »

3rd Annual Consumer…

LNCE

Snyder's-Lance

$36.81

0.23 (0.63%)

LVS

Las Vegas Sands

$62.47

1.35 (2.21%)

SAP

SAP

$82.99

-0.14 (-0.17%)

TSN

Tyson Foods

$57.39

0.12 (0.21%)

TUP

Tupperware Brands

$55.46

0.24 (0.43%)

CDXC

ChromaDex

$2.39

0.05 (2.14%)

TVIA

Tvia, Inc.

$1.25

0.1 (8.70%)

HRL

Hormel Foods

$33.31

-0.48 (-1.42%)

RCL

Royal Caribbean

$81.15

0.1 (0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 13

    Dec

  • 09

    Jan

RKDA

Arcadia Biosciences

, SEED

Origin Agritech

$2.50

0.02 (0.81%)

07:28
12/07/16
12/07
07:28
12/07/16
07:28
Conference/Events
UBS to hold a conference »

2016 UBS Agriculture Day…

RKDA

Arcadia Biosciences

SEED

Origin Agritech

$2.50

0.02 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

OSIS

OSI Systems

$76.45

0.51 (0.67%)

, ZIXI

ZixCorp

$4.45

0.03 (0.68%)

07:27
12/07/16
12/07
07:27
12/07/16
07:27
Conference/Events
Imperial Capital to hold a conference »

2016 Security Investor…

OSIS

OSI Systems

$76.45

0.51 (0.67%)

ZIXI

ZixCorp

$4.45

0.03 (0.68%)

APDN

Applied DNA Sciences

$2.25

0.05 (2.27%)

ASCMA

Ascent Capital

$18.00

-0.19 (-1.04%)

BCO

Brink's

$39.95

0.9 (2.30%)

CTRL

Control4

$11.20

0.01 (0.09%)

NSSC

NAPCO Security

$8.15

0.15 (1.88%)

VRNT

Verint

$38.20

0.15 (0.39%)

INVE

Identiv

$2.58

0.11 (4.45%)

QLYS

Qualys

$32.25

-0.25 (-0.77%)

TASR

TASER

$28.19

0.11 (0.39%)

PCTI

PCTEL

$5.06

0.09 (1.81%)

RDWR

Radware

$13.64

0.07 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

CGEN

Compugen

$6.10

0.1 (1.67%)

07:26
12/07/16
12/07
07:26
12/07/16
07:26
Hot Stocks
Compugen discloses cancer immunotherapy program for TIGIT »

Compugen disclosed today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CS

Credit Suisse

$14.69

1.01 (7.38%)

07:25
12/07/16
12/07
07:25
12/07/16
07:25
Conference/Events
Credit Suisse to hold a conference »

2016 Quantitative…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 14

    Dec

EW

Edwards Lifesciences

$83.22

0.73 (0.88%)

07:25
12/07/16
12/07
07:25
12/07/16
07:25
Recommendations
Edwards Lifesciences analyst commentary  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ARGS

Argos Therapeutics

$4.75

0.05 (1.06%)

07:25
12/07/16
12/07
07:25
12/07/16
07:25
Conference/Events
Argos Therapeutics to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

TCRD

THL Credit

$10.32

-0.02 (-0.19%)

, FSIC

FS Investment

$10.05

-0.05 (-0.50%)

07:24
12/07/16
12/07
07:24
12/07/16
07:24
Conference/Events
Wells Fargo to hold a forum »

2016 Middle Market…

TCRD

THL Credit

$10.32

-0.02 (-0.19%)

FSIC

FS Investment

$10.05

-0.05 (-0.50%)

BKCC

BlackRock Capital Investment

$7.41

0.08 (1.09%)

NMFC

New Mountain Finance

$14.20

-0.05 (-0.35%)

SLRC

Solar Capital

$20.67

0.14 (0.68%)

TCPC

TCP Capital

$16.95

-0.03 (-0.18%)

MAIN

Main Street

$36.37

-0.04 (-0.11%)

TSLX

TPG Specialty Lending

$18.49

0.12 (0.65%)

HTGC

Hercules Capital

$13.62

-0.12 (-0.87%)

KKR

KKR

$15.87

0.2 (1.28%)

TROW

T. Rowe Price

$76.09

0.51 (0.67%)

APO

Apollo Global

$19.28

0.03 (0.16%)

BX

Blackstone

$26.55

0.15 (0.57%)

GS

Goldman Sachs

$231.38

2.83 (1.24%)

WFC

Wells Fargo

$55.55

1.2 (2.21%)

ARCC

Ares Capital

$16.31

0.17 (1.05%)

MCC

Medley Capital

$7.63

-0.04 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

  • 12

    Dec

  • 13

    Dec

  • 15

    Dec

WDC

Western Digital

$63.85

1.76 (2.83%)

07:24
12/07/16
12/07
07:24
12/07/16
07:24
Recommendations
Western Digital analyst commentary  »

Brean Capital ups Western…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.